Sachin Tendulkar encourages consumers to look beyond ‘organic labels' in new ad
Tata Consumer Products
, has launched a new campaign to reinforce Organic India as one of India's most trusted organic brands, in collaboration with cricket legend Sachin Tendulkar.
Tendulkar's determination to excellence and integrity mirrors the brand's unwavering commitment to deliver high quality, trusted
organic products
, the company stated in a press note.
With this natural alignment of shared values and vision, Organic India aims to deepen consumer trust, inspire brand love and reinforce its position as a pioneer in the
organic foods and beverages
category, it added.
Anchored in the message 'Sirf Naam Se Nahi, Kaam Se Organic', the campaign is launched at a time when consumer interest in
healthier eating
and
organic food
is steadily rising.
However, as more people make conscious choices, many remain uncertain about what truly defines an organic product. The market is flooded with claims, leaving consumers questioning the integrity behind the organic label.
This campaign encourages consumers to ask the right questions and educates them on identifying authentically organic products while reinforcing the rigorous quality standards Organic India products adhere to, which makes them 'authentically organic'. By backing every claim with proof, Organic India aims to help consumers go beyond just an 'Organic label' and make decisions rooted in facts and not assumptions.
The brand film brings this message to life through everyday moments which most consumers can relate to. With calm conviction, Tendulkar gently reminds consumers to look beyond just Organic labels, challenge assumptions about the authenticity of the so-called Organic products, while drawing attention to what sets Organic India apart.
As Tendulkar shares in the film, 'Sirf Naam se nahi, Kaam se organic,' He adds, 'In today's world, it's important to ask where your food comes from and how it's grown. What drew me to Organic India is their integrity; everything they say, they back up with action. This film reflects that honesty and encourages people to choose with care.'
Puneet Das, president – packaged beverages, India and South Asia, Tata Consumer Products, said, 'With this campaign, we are urging the consumers to question the authenticity of various Organic products and reinforce what truly makes a product organic. Organic India has always believed that authenticity must be earned, not claimed. Through rigorous testing, transparent sourcing, and a legacy of integrity, we aim to build lasting trust. Tendulkar's voice brings powerful credibility to this mission, inspiring people to make choices rooted in truth, not assumptions.'
The campaign will be amplified through a multi-platform rollout including digital, influencer engagement, and community storytelling.
This campaign was conceptualised and developed by Creativeland Asia Advertising.
Watch the video here:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
an hour ago
- News18
Tata Consumer Products Shares Jump 4% After 15% YoY Rise In Q1 Profit; Should You Buy?
Last Updated: Tata Consumer Products shares surged 4% to an intraday high of Rs 1,104.80 on the BSE on Thursday; Good time to invest? Tata Consumer Products shares surged 4% to an intraday high of Rs 1,104.80 on the BSE on Thursday after the company posted its earnings for the first quarter of FY26. The FMCG major reported a 15% year-on-year rise in consolidated net profit at Rs 334 crore, compared to Rs 290 crore in the same quarter last year. Revenue from operations rose 10% to Rs 4,779 crore, up from Rs 4,352 crore in Q1FY25. However, both profit and revenue missed Street estimates, which were pegged at Rs 355 crore and Rs 4,813 crore, respectively. Despite the topline growth, the company's consolidated EBITDA declined by 8% on a yearly basis, while EBITDA margins contracted over 250 basis points to 12.7%. The drop was largely attributed to corrections in coffee prices within the non-branded segment. Tata Consumer expects margins in its branded tea business to improve by the third quarter of FY26, aided by moderating auction prices and better pass-through of input costs. The management also noted that performance improvements in NourishCo and Capital Foods remain key focus areas for driving future growth. Among brokerages, CLSA maintained a 'Hold' rating while raising its target price to Rs 1,065 from Rs 1,044. Citi retained a 'Buy' call but trimmed its target to Rs 1,275 from Rs 1,325, citing weak Q1 results and a mixed profitability outlook. Morgan Stanley remained 'Overweight' on the stock with a target price of Rs 1,255, highlighting the 10% year-on-year revenue growth and better-than-expected margins. JP Morgan and Jefferies both maintained 'Neutral/Hold' ratings, setting a target price of Rs 1,100. Nomura, meanwhile, reiterated its 'Buy' call with a target price of Rs 1,300. view comments First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Economic Times
an hour ago
- Economic Times
Buy, Sell or Hold: Antique maintains Hold on Infosys; Nuvama maintains Buy on Dr Reddy's Laboratories
Live Events Antique on Infosys: Hold | Target price: Rs 1,750 Nuvama on Dr. Reddy's Laboratories: Buy | Target: Rs 1,486 | LTP: Rs 1,247 | Upside: 19% Motilal Oswal on Tata Consumer Products: Buy | Target: Rs 1,270 (earlier Rs 1,300) | LTP: Rs 1,062 | Upside: 19% (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Brokerages have shared their latest views on key Indian stocks, highlighting a mix of steady performance, emerging growth drivers, and sector-specific Antique has maintained a cautious stance on Infosys , citing margin pressures and limited changes in organic growth guidance, Nuvama remains optimistic about Dr. Reddy's Laboratories, driven by pipeline progress and a strong outlook for its CDMO Motilal Oswal has reiterated its bullish view on Tata Consumer Products , expecting margin expansion and synergies from recent acquisitions to support earnings a summary of their recommendations and insights for the next 12 have compiled key brokerage recommendations from ET Now and other sources:Antique has maintained a 'Hold' rating on Infosys with a target price of Rs 1,750. While the company delivered a strong quarterly performance, its organic growth guidance remains largely reported a robust total contract value (TCV) of $3.8 billion, reflecting solid deal bookings. However, discretionary spending remains weak, and the company continues to face margin headwinds. As a result, EPS estimates for FY26 and FY27 remain has maintained a 'Buy' rating on Dr. Reddy's Laboratories with a target price of Rs 1,486, implying a 19% upside from the last traded price of Rs 1, the company's Q1 performance was below expectations, new growth drivers are emerging. Semaglutide's progress in Canada remains on track, and a US filing for Abatacept is expected—both positive CDMO business is expected to contribute $100 million in FY26, with a target of reaching $300 million by FY30—a significant upside the company has reaffirmed its 25% margin guidance, backed by ongoing cost optimisation Oswal has reiterated its 'Buy' rating on Tata Consumer Products, revising the target price slightly to Rs 1,270 from Rs 1,300, indicating a 19% upside from the current price of Rs 1, brokerage expects moderating tea prices to support margin expansion starting Q2FY26. Consolidated margins are likely to improve, led by the tea business, while the international segment is expected to sustain its from the integration of Capital Foods and Organic India are also expected to boost the domestic food segment. The company has guided for ~16% EBITDA margin by has accordingly raised its EBITDA estimates for FY26 and FY27 by 7% and 3%, respectively.
Economic Times
an hour ago
- Economic Times
Tata Consumer Products shares rally 4% after Q1 results. Should you buy, sell or hold?
Tata Consumer Products shares rallied 4% to an intraday high of Rs 1,104.80 on the BSE on Thursday after the company reported a 15% year-on-year (YoY) rise in consolidated net profit to Rs 334 crore for Q1FY26, compared to Rs 290 crore in the year-ago period. ADVERTISEMENT Revenue from operations rose 10% to Rs 4,779 crore, up from Rs 4,352 crore in Q1FY25. However, both profit and revenue came in below Street estimates of Rs 355 crore and Rs 4,813 crore, respectively. On a sequential basis, revenue grew 3.7% from Rs 4,608 crore in Q4FY25, while profit remained flat. Consolidated EBITDA fell 8%, primarily due to higher tea costs in India and price corrections in the non-branded coffee segment. EBITDA margin stood at 12.9%, down 250 basis points the India branded business, underlying volume growth (UVG) was 6.8%, with core categories like tea and salt posting double-digit growth. The company's 'growth' portfolio registered an overall 7% international business continued to perform well, with 5% constant-currency revenue growth, driven by strong coffee sales in the US. ADVERTISEMENT Motilal Oswal has retained its 'Buy' rating but cut the target price to Rs 1,270 from Rs 1,300. ADVERTISEMENT The brokerage expects margin expansion from Q2FY26 as tea prices moderate. It sees consolidated margins improving, led by the tea segment, and anticipates continued growth in the international business. Additionally, synergies from Capital Foods and Organic India are expected to support growth in the domestic food segment. The company has guided for ~16% EBITDA margin by Q3FY26. Motilal has raised its FY26/FY27 EBITDA estimates by 7% and 3%, respectively. ADVERTISEMENT Nuvama has maintained its 'Buy' rating while lowering the target price to Rs 1,285 from Rs 1, brokerage expects easing tea costs to relieve margin pressure, although overall margins remain constrained. It projects EBITDA to outpace revenue growth from H2FY26. Tea volumes are expected to grow in the mid-single digits, with value growth of 6–8%. EBITDA margin is seen returning to the 14–16% range from Q2FY26. However, Nuvama has cut its FY26 and FY27 EPS estimates by 4.2% and 2.6%, respectively. (Disclaimer: Recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of The Economic Times) ADVERTISEMENT (You can now subscribe to our ETMarkets WhatsApp channel)
